Boston Scientific’s (NYSE:BSX) Revenue from Peripheral Interventions rose from about $1.4 billion in 2019 to about $1.6 billion in 2020. Trefis expects the metric to rise to around $1.9 billion in 2021 and around $2.1 billion in 2022.
- What’s Next For Boston Scientific Stock After 5% Gains In A Week?
- Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?
- Which Is A Better Buy – Boston Scientific Stock Or Abbott?
- What’s Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
- New Product Launches To Aid Boston Scientific’s Q1
- Will Boston Scientific Stock See Higher Levels?
We expect sales growth to be driven by product portfolio improvements and market factors, including the rising incidence of people suffering from Peripheral Vascular Diseases (PVD) and other conditions.
We think BSX stock is undervalued. We value BSX at about $50 per share, about 30% ahead of the current market price.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
|S&P 500 Return||1%||24%||108%|
|Trefis MS Portfolio Return||-2%||48%||300%|
 Month-to-date and year-to-date as of 11/30/2021
 Cumulative total returns since 2017